Volkswagen AG (VW) is looking to raise as much as 9.4 billion euros (US$9.41 billion) from the initial public offering (IPO) of its iconic sports-car maker Porsche AG in what could be Europe’s largest listing in more than a decade.
The German automaker late on Sunday said that it is seeking a valuation of 70 billion to 75 billion euros for the listing, below an earlier top-end goal of as much as 85 billion euros, with the deal going ahead at a time of deep market upheaval.
European markets have been largely shut to IPOs for most of the year, with companies shying away from seeking new listings because of the region’s energy crisis, rising interest rates and record inflation.
Photo: Bloomberg
Amid the stock market slump, the plan to list is getting a boost from firm commitments of key cornerstone investors. Qatar Investment Authority, Norway’s sovereign wealth fund, T. Rowe Price Group Inc and Abu Dhabi Developmental Holding Co are set to subscribe to preferred shares of as much as 3.7 billion euros, the manufacturer said.
“We are now in the home stretch with the IPO plans for Porsche and welcome the commitment of our cornerstone investors,” VW chief financial officer Arno Antlitz said.
The offer period is to start today with a planned trading start on Thursday next week.
During meetings with potential investors, VW pitched the listing as a chance to invest in a company that combines the best of automaking rivals like Ferrari NV and luxury brands such as Louis Vuitton.
While Ferrari and Porsche both target wealthy buyers, the Italian manufacturer remains in league of its own, boasting industry-leading margins and delivering a fraction of Porsche’s 300,000 annual sales.
Aside from offering investors a slice of one of the most recognizable names in automaking, the IPO would hand back significant decisionmaking power to the Porsche-Piech family, who lost control of the sports-car maker more than a decade ago after a protracted takeover battle with VW.
To account for the interests of the billionaire family, who hold 53 percent of VW’s voting shares via the separately listed Porsche Automobil Holding SE, the Porsche IPO is complex and has triggered governance concerns that mirror those about VW’s convoluted structure.
Investors would be able to subscribe to 25 percent of Porsche preferred shares, which carry no voting rights. The family is to buy 25 percent plus one of Porsche’s common shares with voting rights, meaning they would receive a minority blocking stake and sway on key decisions.
The family has agreed to pay a 7.5 percent premium on top of the price range for the preferred shares and plans to fund the acquisition with a mix of debt capital of as much as 7.9 billion euros and a special dividend paid out by VW.
Proceeds from the deal would help VW with financing its electric vehicle transition and investments in software, the automaker has said.
While interest for the IPO has been high, some investors have said the appointment of Porsche CEO Oliver Blume to the helm of VW and the plan for him to stay on in a dual role raises questions about Porsche’s independence.
This time was supposed to be different. The memorychip sector, famous for its boom-and-bust cycles, had changed its ways. A combination of more disciplined management and new markets for its products — including 5G technology and cloud services — would ensure that companies delivered more predictable earnings. Yet, less than a year after memory companies made such pronouncements, the US$160 billion industry is suffering one of its worst routs ever. There is a glut of the chips sitting in warehouses, customers are cutting orders and product prices have plunged. “The chip industry thought that suppliers were going to have better control,” said
Enimmune Corp (安特羅生技) has obtained marketing approval from the Food and Drug Administration (FDA) for its EnVAX-A71 vaccine for enterovirus 71 (EV-71), becoming the nation’s first enterovirus vaccine completely made in Taiwan, it said yesterday. After spending 13 years and NT$1.5 billion (US$49.77 million) on the research and development of the vaccine, Enimmune plans to start manufacturing and marketing it by the end of March, the company said in a statement, without disclosing customer order figures. “It is possible that the vaccine would not be included in a national vaccination program initially, and consumers would need to pay for it themselves,” parent
Vaccine skeptics blocking transfusions for life-saving surgeries, Facebook groups inciting violence against doctors and a global search for unvaccinated donors — COVID-19 misinformation has bred a so-called “pure blood” movement. The movement spins anti-vaccine narratives focused on unfounded claims that receiving blood from people inoculated against COVID-19 “contaminates” the body. Some have advocated for blood banks that draw from “pure” unvaccinated people, while medics in North America say they have fielded requests from people demanding transfusions from donors who have not received a vaccine. In closed social media groups, vaccine skeptics — who brand themselves as “pure bloods” — promote violence against doctors
Asteroid mining start-up AstroForge Inc is planning to launch its first two missions to space this year as it seeks to extract and refine metals from deep space. The first launch, scheduled for April, is to test AstroForge’s technique for refining platinum from a sample of asteroid-like material. The second, planned for October, would scout for an asteroid near Earth to mine. The missions are part of AstroForge’s goal of refining platinum-group metals from asteroids, with the aim of bringing down the cost of mining these metals. It also hopes to reduce the massive amount of carbon emissions that stem from mining
RSS